HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eslicarbazepine acetate: an update on efficacy and safety in epilepsy.

Abstract
Epilepsy is a common neurological disorder. Despite a broad range of commonly used antiepileptic drugs, approximately 30% of patients with epilepsy have drug resistance or encounter significant adverse effects. Eslicarbazepine acetate is a new central nervous system-active compound with anticonvulsant activity whose mechanism of action is by blocking the voltage-gated sodium channel. Eslicarbazepine acetate was approved by the European Medicines Agency and launched onto the European market in 2009 for adjunctive treatment in adult subjects of partial-onset seizures, with or without secondary generalization. This article provides an overview on the recent studies on eslicarbazepine acetate in the treatment of drug-resistant partial epilepsy. Efficacy and safety of this drug for partial-onset seizures were assessed in four randomized clinical trials with responder rates ranged between 17% and 43%. Adverse events were usually mild to moderate in intensity and the most common were dizziness, somnolence, nausea, diplopia, headache, vomiting, abnormal coordination, blurred vision, vertigo and fatigue. Eslicarbazepine acetate is not recommended below 18 years, but a published phase II trial had the main goal to evaluate the pharmacokinetics, efficacy and safety of this drug in pediatric population. Eslicarbazepine acetate appears to be a safe and effective drug with a linear pharmacokinetics, very low potential for drug-drug interactions and therefore it can offer a valid alternative to current antiepileptic drugs. Additionally, it is undergoing investigation for monotherapy in subjects with partial epilepsy, and other neurological and psychiatric disorders.
AuthorsAlberto Verrotti, Giulia Loiacono, Alessandra Rossi, Gaetano Zaccara
JournalEpilepsy research (Epilepsy Res) Vol. 108 Issue 1 Pg. 1-10 (Jan 2014) ISSN: 1872-6844 [Electronic] Netherlands
PMID24225327 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2013 Elsevier B.V. All rights reserved.
Chemical References
  • Anticonvulsants
  • Dibenzazepines
  • eslicarbazepine acetate
Topics
  • Animals
  • Anticonvulsants (adverse effects, pharmacokinetics, therapeutic use)
  • Clinical Trials as Topic (methods)
  • Dibenzazepines (adverse effects, pharmacokinetics, therapeutic use)
  • Epilepsy (drug therapy, metabolism)
  • Humans
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: